<DOC>
	<DOCNO>NCT00648076</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's divalproex sodium 500 mg extended-release tablet Abbott 's Depakote ER® 500 mg tablet follow single , oral 500 mg ( 1 x 500 mg ) dose administer fed condition .</brief_summary>
	<brief_title>Food Study Divalproex Sodium Extended-Release Tablets 500 mg Depakote ER® Tablets 500 mg</brief_title>
	<detailed_description />
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Age : 18 year old . 2 . Sex : Male . 3 . Weight : At least 60 kg ( 132 lb ) within 15 % Ideal Body Weight ( IBW ) , reference Table `` Desirable Weights Adults '' Metropolitan Life Insurance Company , 1999 ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 4 . All subject judge normal healthy prestudy medical evaluation ( physical examination , include vital sign , laboratory evaluation , 12lead ECG , hepatitis B hepatitis C test , HIV test , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiates , phencyclidine , methadone ) perform within 14 day initial dose study medication . 5 . During course study , study screen study exit , male must use spermicidecontaining barrier method contraception addition current contraceptive device ( ) . This requirement document informed consent form . 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobacco product within 1 year start study . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 5 . A positive test drug include urine drug screen . 6 . History drug and/or alcohol abuse . 3 . Medications : 1 . Use prescription overthecounter ( OTC ) medication within 14 day prior initial dose study medication . 2 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 4 . Diseases : 1 . History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic disease . 2 . Acute illness time either prestudy medical evaluation dosing . 3 . A positive HIV , hepatitis B , hepatitis C test . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 2 . Abnormal clinically relevant ECG tracing . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity valproic acid related product . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Consumption grapefruit grapefruit containing product within 7 day drug administration .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>